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ABSTRACT. Objective.Methotrexate-associated lymphoproliferative disorders (MTX-LPD) often regress sponta-
neously during MTX withdrawal, but the prognostic factors remain unclear. The aim of our study
was to clarify the clinical, histological, and genetic factors that predict outcomes in patients with
MTX-LPD.
Methods. Patients with MTX-LPD diagnosed between 2000 and 2012 were analyzed retrospectively
regarding their clinical course, site of biopsy, histological typing, Epstein-Barr virus (EBV) in situ
hybridization and immunostaining, and HLA type.
Results. Twenty-one patients, including 20 with rheumatoid arthritis (RA) and 1 with polymyositis,
were analyzed. The mean dose of MTX was 6.1 mg/week and the mean duration of treatment was
71.1 months. Clinically, 5 patients were diagnosed with EBV-positive mucocutaneous ulcer
(EBVMCU) and had polymorphic histological findings. The proportion of those patients success-
fully treated solely by withdrawal of MTX was significantly greater than that of those without
EBVMCU (75% vs 7.7%, p = 0.015). The HLA-B15:11 haplotype was more frequent in patients
with EBV+ RA with MTX-LPD than in healthy Japanese controls (p = 0.0079, Bonferroni’s
method). EBV latency classification and HLA typing were not associated with the prognosis of
MTX-LPD in our cohort.
Conclusion. Our data demonstrate that patients in the EBVMCU, a specific clinical subgroup of
MTX-LPD, had a better clinical outcome when MTX was withdrawn than did other patients with
MTX-LPD. (First Release Dec 15 2013; J Rheumatol 2014;41:293–9; doi:10.3899/jrheum.130270)
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Methotrexate (MTX)-associated lymphoproliferative dis-
orders (LPD) are a lymphoid proliferation or lymphoma
that occur in patients immunosuppressed with MTX,
classified as a part of the “other iatrogenic immunodefi-
ciency-associated lymphoproliferative disorders” category
by the World Health Organization (WHO) in 20081.
Because MTX has recently gained acceptance as a first-line
therapy for rheumatoid arthritis (RA)2,3 and other systemic
rheumatic diseases (SRD), the incidence of MTX-LPD is
expected to increase. A better understanding of this
important disease is somewhat limited by its rarity.
Epstein-Barr virus (EBV) infection is thought to play an
important role in the pathogenesis of MTX-LPD, although
EBV can only be detected on histopathologic examination
in about half the cases of MTX-LPD4.
    Under normal circumstances, EBV-specific cytotoxic T
lymphocytes (EBV-CTL) act to suppress EBV-infected B
cells. However, if the function of EBV-CTL is impaired by
immunosuppressants, such as MTX or by aging,
EBV-infected B cells are reactivated to induce B cell prolif-
eration, leading to the development of LPD. There is specu-
lation that MTX could reactivate latent EBV infection,
because patients with SRD treated with regimens that
include MTX have higher mean EBV loads in their blood
than those who do not5. EBV-related LPD (EBV-LPD) can
be categorized into 3 types on the basis of their expression
of EBV-encoded small RNA (EBER), EBV latent
membrane protein-1 (LMP1), and EBV nuclear antigen-2
(EBNA2): latency I  (EBER+, LMP-1–, EBNA2–) as seen
in Burkitt’s lymphoma; latency II (EBER+, LMP-1+,
EBNA-2–) as seen in Hodgkin’s lymphoma or naso-
pharyngeal carcinoma; and latency III (EBER+, LMP-1+,
EBNA-2+) as seen in posttransplant LPD (PT-LPD)6.
EBV-LPD frequently occurs in immunosuppressed patients
and its prognosis appears to vary widely.
    LPD with EBV-positive mucocutaneous ulcer
(EBVMCU) has been reported as a distinct disease entity
with a self-limiting and indolent clinical course7. EBVMCU
is found in various conditions of immunosuppression,
including MTX-LPD or in age-related immunosenescence.
The latter is characterized by age-related EBV+ B cell LPD
(Age-LPD) on a background of EBV infection in elderly
patients without immunodeficiency8. Although MTX-LPD
often shows spontaneous regression, it is not clear whether
MTX-LPD with EBVMCU has a better prognosis. The aim
of our study was to clarify the clinical, histological, and
genetic factors predictive of a good prognosis in patients
with MTX-LPD.
MATERIALS AND METHODS
Patients. Twenty-one patients with SRD who developed MTX-LPD
between 2000 and 2012 were included in our study. There were 20 with RA
and 1 with polymyositis (PM). Of the 20 patients with RA, 3 had RA
overlapping with Sjögren syndrome (SS), 1 had RA with systemic lupus
erythematosus (SLE), and 1 had RA with polymyalgia rheumatica (PMR).
The diagnoses of RA, PM, SS, SLE, and PMR were made according to the
American College of Rheumatology classification criteria. The stage of RA
was evaluated by Steinbrocker’s classification and the stage of LPD by Ann
Arbor classification. After the histologic diagnosis of MTX-LPD was
made, MTX was withdrawn in all patients. Necessity of chemotherapy was
determined according to the histology, karyotypes, stages, or clinical
judgment of poor response to MTX withdrawal. 
Ethics statement. The study was conducted in compliance with the
Declaration of Helsinki and was approved by the Kyoto University Ethics
Committee Review Board; written informed consent was obtained from all
patients.
Histological analysis. Two pathologists performed histological analysis of
specimens from each patient. Diagnoses were made in accordance with the
criteria specified in WHO Tumors of Hematopoietic and Lymphoid Tissues,
fourth edition1. Immunostaining of paraffin sections was performed using
monoclonal antibodies against LMP1 (Clone CS.1-4, Dako) and EBNA2
(M7004, PE2, Dako). The presence of EBER was determined by in situ
hybridization (ISH) using a peptide nucleic acid (PNA) ISH detection kit
(K5201, Dako) and an EBER PNA Probe/Fluorescein kit (Y5200, Dako).
Typing of HLA. HLA-A, B, and DR typing studies of 16 cases of RA with
MTX-LPD and 96 control cases of RA without MTX-LPD diagnosed in
our department were undertaken using the PCR-Luminex method. The
frequency of each HLA allele was analyzed with reference to the Japanese
HLA laboratory database (http://hla.or.jp/haplo/haplonavi.php?type=haplo
&lang=ja), which includes over 20,000 cases. 
Statistical analysis. Data are expressed as mean ± SD. Comparisons of
HLA and histological data were made using Fisher’s exact test. Each allele
seen in more than 2 cases was assessed with significant level corrected p
value (Pc) by Bonferroni’s method. A Kaplan-Meier plot of the
chemotherapy-free survival was evaluated by the log-rank test. All analyses
were performed using PASW Statistics 18 (18.0.0) and statistical signifi-
cance was defined as p < 0.05.
RESULTS
Clinical and pathological details of patients with
MTX-LPD. The clinical, pathological, and genetic character-
istics of 21 cases of MTX-LPD are shown in Table 1; 17
(81%) were female; the mean age was 65.8 ± 7.5 years
(range 52 to 79 yrs). The average dose of MTX was 6.1 ±
1.7 mg/week; treatment duration was 71.1 ± 57.8 months.
Staging of RA was undertaken using Steinbrocker’s classifi-
cation; 1 patient fulfilled the criteria for stage I, 3 for stage
II, 3 for stage III, and 13 for stage IV. Three patients (cases
1, 5, and 15) were treated with infliximab. Seventeen out of
20 RA cases (85%) were rheumatoid factor (RF)-positive
and 7 out of 14 cases (50%) were anticitrullinated protein
antibody (ACPA)-positive.
    The pathological findings were as follows: 10 cases were
diagnosed with diffuse large B cell lymphoma (DLBCL), 7
with polymorphic lymphoproliferative disorder (p-LPD), 3
with HL, and 1 with small B cell lymphoma that later trans-
formed into DLBCL. The biopsy site was extranodal in 12
cases (57%); all 7 cases of p-LPD were extranodal, while 3
cases of HL were nodal. Of the 10 cases of DLBCL, half
were extranodal and half nodal. Twelve out of 20 cases
(60%) were EBER-positive, while 8 cases of 19 (42%) were
LMP1-positive and 3 cases out of 19 (16%) were
EBNA2-positive. EBV latency was classified by means of
EBER, LMP1, and EBNA2 expression into 4 groups:
EBV-negative and latencies I–III. Representative histo-
logical images are shown in Figure 1. The cases diagnosed
as p-LPD comprised 7 of the 12 patients in latency I–III
groups; but there were none among the 8 patients in the
EBV-negative group (p = 0.012). Extranodal involvement
was found in 8 of 12 patients in the latency I–III groups but
only 3 of 8 in the EBV-negative group. EBVMCU was
diagnosed in 5 cases (cases 1, 2, 4, 5, and 21), each charac-
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terized by sharply demarcated skin ulcers with an erythe-
matous appearance accompanied by crusting and necrosis
(Figure 2) which, on histological examination, were found
to be polymorphic with a mixture of lymphocytes and
immunoblasts. Lymphocytic vasculitis was seen in 3 out of
5 cases (cases 2, 5, and 21). Four out of 5 cases (80%) of
EBVMCU were seropositive. 
HLA typing of patients with MTX-LPD. As shown in Table
2, we found that 3 cases out of 16 were heterozygous for the
HLA-B15:11 allele. The allele frequency of HLA-B15:11
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Table 1. Clinical and pathological findings in 21 cases of methotrexate-associated lymphoproliferative disorders (MTX-LPD).
No. Age  Sex  DiseaseDose ofDuration   E/N      Site of Biopsy   Histology   EBER LMP1 EBNA2  EBV  LPD   IPI      Therapy and Response    Response  Prognosis   Followup
                                     MTX,  of MTX,                                                                                              LatencyStage                                                        (final                          period,
                                       mg/        mos                                                                                                                                                                                state)                             mos
                                      week
1       76     F       RA        8.0          27    E(MCU)     left eyelid         p-LPD        (+)       (+)        (+)        III        I        L                  W → CR                   CR              A               24
2       64     F       RA        8.0         120   E(MCU)  buccal mucosa     p-LPD        (+)       (+)        (+)        III      IV     HI                       W                         ND           D#1              1
3       71     F       RA        8.0         184         E           left latero-        p-LPD        (+)       (+)        (+)        III      IV      H      R-CHOP → PR → oral       CR              A               31
                                                                           abdominal nodule                                                                                                VP-16 → CR                   
4       59     F       RA        5.0          63    E(MCU)     left eyelid         p-PLD        (+)       (+)        (–)         II        I       H                  W→ CR                    CR              A               37
5       61     F       RA       10.0         74    E(MCU)     right lower        p-PLD        (+)       (+)        (–)         II       IV      H            R-CHOP → CR              CR              A               25
                                                                                   leg ulcer
6       65     F     RA SS     4.0          27          N          left axillary          HL           (+)       (+)        (–)         II        II      LI      W → CR → relapse →        CR              Α               79
                                                                                lymph node                                                                                         ABVD, C-MOPP → PR →
                                                                                                                                                                                                          RT → CR
7       65     F       RA        5.0          66          N         right axillary         HL           (+)       (+)        (–)         II       IV     HI      W → CR → relapse →        CR            D#2             17
                                                                                lymph node                                                                                                    ABVD → CR  
8       58     F       RA        4.0          66          N       inguinal lymph      SBL          (+)       (+)        (–)         II        II       L  CHOP, RT → CR → relapse   CR            D#3             92
                                                                                      node                                                                                           → observe → R-ICE, CHASER, 
                                                                                                                                                                                          auto-PBSCT (MEAM) → CR
9       67     F     RA SS     6.0          16          E         parotid gland     DLBCL       (+)       (–)        (–)         I        III      H   R-CHOP → CR → relapse     PD              D               90
                                                                                                                                                                                             → R-DeVIC → PR → RT, 
                                                                                                                                                                                            CHASER, R-ESHAP, mini-
                                                                                                                                                                                          MEAM, GEM, CPT-11 → PD
10     61     F       RA        6.0         193        N         right cervical     DLBCL       (+)       (–)        (–)         I        III      LI            R-CHOP → CR              CR              A               45
                                                                                lymph node
11     79    M      RA        8.0         169         E         right forearm      p-LPD        (+)       (–)        (–)         I         I       LI                 W → CR                   CR              A                9
12     66    M      RA        6.0          46          N     left submandibular  DLBCL       (–)       (–)        (–)         n       IV     HI      R → CR → relapse →        PD              D               27
                                                                                lymph node                                                                                                    CHOP → PD
13     72     F   RA SLE    6.0         ND         N     right submandibular DLBCL       (–)       (–)        (–)         n        II      LI   R-CHOP → CR → relapse     PD              A               48
                                                                                lymph node                                                                                                     → R-DeVIC
14     74     F       RA        7.0          74          N         right cervical     DLBCL       (–)       (–)        (–)         n        II      LI                 W → CR                   CR              A               32
                                                                                lymph node
15     52     F     RA SS     5.0          47          E       precordial skin    DLBCL       (–)       (–)        (–)         n       IV     HI            R-CHOP → CR              CR              A               84
16     76    M      RA        4.0         ND         N         right axillary         HL           (–)       (–)        (–)         n       III     HI                       W                         ND             A                1
                                                                                lymph node
17     71    M  RA PMR   5.0           7           N         right cervical     DLBCL       (–)       (–)        (–)         n        II      HI            R-CHOP → PR              PR              A                8
                                                                                lymph node
18     62     F       RA        8.0          21          E          right orbital      DLBCL       (–)       (–)        (–)         n        II      LI            R-CHOP → CR              CR              A               15
                                                                                     fossa
19     56     F       RA        5.5          98          E    left submandibularDLBCL       (–)       (–)        (–)         n        II       L                  W → CR                   CR              A               14
                                                                                      skin
20     71     F       RA        6.0          48          E         lumbar mass     DLBCL       NE      NE       NE       ND      II      LI         R-CHOP, RT → CR           CR              A              132
21     56     F       PM       4.0           4     E(MCU)      left lower         p-LPD        (+)      NE       NE       ND       I        L                  W → CR                   CR              A               33
                                                                                   leg ulcer               
No. 1: Died soon from intercurrent disease (myelitis and sepsis). No. 2: Died from bleomycin-induced interstitial pneumonia. No. 3: died from pneumocystis pneumonia. PM:
polymyositis; RA: rheumatoid arthritis; SS: Sjögren syndrome; SLE: systemic lupus erythematosus, PMR: polymyalgia rheumatica; E: extranodal; MCU: mucocutaneous ulcer
lesion; N: nodal; EBV: Epstein-Barr virus; DLBCL: diffuse large B cell lymphoma; EBER: EBV-encoded small RNA; p-LPD: polymorphic lymphoproliferative disorder; SBL:
small B cell lymphoma; HL: Hodgkin lymphoma; n: EBV-negative; NE: not examined; ND: not determined; IPI: international prognostic index; L: low risk; LI: low-intermediate
risk; HI: high-intermediate risk; H: high risk; W: withdrawal of MTX only; R-CHOP: rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone; ABVD:
adriamycin, bleomycin, vinblastine and dacarbazine; C-MOPP: cyclophosphamide, vincristine, prednisolone and procarbazine; RT: radiotherapy; R-ICE: rituximab, ifosfamide,
carboplatin and etoposide; MEAM: ranimustine (MCNU), etoposide, cytarabine and melphalan; R-DeVIC: rituximab, dexamethasone, etoposide, ifosfamide and carboplatin; 
R-ESHAP: rituximab, etoposide, prednisolone, high-dose cytarabine and cisplatin; GEM: gemcitabine; CPT-11: irinotecan; CR: complete remission; PD: progressive disease; PR:
partial remission; A: alive; D: dead; auto-PBSCT: autologous peripheral blood stem cell transplantation; CHASER: cyclophosphamide, cytarabine, dexamethasone, etoposide, and
rituximab
was higher in EBV+ RA with MTX-LPD, compared with
the control JHD group and that of the Japanese RA cohort
(Pc = 0.0079 and 0.024, respectively, Table 3). RA-shared
epitopes were observed in 11 of 16 cases (69%), a signifi-
cantly higher proportion than in healthy Japanese controls
(38%, n = 1508; p = 0.018), but not in Japanese patients with
RA (n = 759)9.
Clinical course of patients with MTX-LPD. MTX was
withdrawn in all cases at the time of LPD diagnosis. When
examining the need for chemotherapy within 18 months of
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Figure 1. Pathological findings in 3 cases of MTX-LPD classified by EBV latency. A-D. DLBCL (case 10, latency I). E-H.
Polymorphic LPD (case 4, latency II). I-L. Polymorphic LPD (case 3, latency III). Pathological findings are shown by H&E (A,
E, I), EBER (B: positive, F: positive, J: positive), LMP1 (C: negative, G: positive, K: positive), and EBNA2 (D: negative, H:
negative, L: positive) staining. MTX-LPD: methotrexate-associated lymphoproliferative disorders; EBV: Epstein-Barr virus;
DLBCL: diffuse large B cell lymphoma; EBER: EBV-encoded small RNA; LMP1: EBV latent membrane protein-1; EBNA2:
EBV nuclear antigen-2.
Figure 2. Two representative cases with skin manifestations of EBV-positive mucocutaneous ulcer (EBVMCU).
Typical skin manifestations of EBVMCU (A: case 5, B: case 2) are shown. Characteristic sharply demarcated skin
ulcers with an erythematous appearance accompanied by crusting and necrosis can be seen.
diagnosis, withdrawal of MTX alone was more successful
for those in the EBVMCU group (n = 4, cases 1, 4, 5, and
21) than the other cases (n = 13; 75% vs 7.7%, p = 0.015;
Figure 3). Because the observation periods were at most 2
years in the majority of cases, we were unable to calculate
longterm prognosis. Five patients (cases 2, 7, 8, 9, and 12)
died; LPD recurred in 2 patients at 90 months (case 9) and
21 months (case 12) from the original diagnosis and did not
respond to continued chemotherapy. One patient (case 2)
died from intercurrent myelitis and sepsis soon after the
diagnosis of LPD and 1 patient (case 7) died from
bleomycin-induced pneumonia. 
    One patient (case 8) was first diagnosed with
EBV-positive small B cell lymphoma (SBL). Although
chemotherapy resulted in partial remission, she had an
indolent clinical course without chemotherapy until the
tumor progressed and histopathological study revealed
EBV-negative DLBCL with the same phenotype as the SBL.
A clonal relationship between the 2 lymphomas was not
proven; however, Richter syndrome was suspected clini-
cally. With regard to the predicted unfavorable prognosis,
she was treated with autologous peripheral blood stem cell
transplantation, but she died of pneumocystis pneumonia
under continuous immunosuppression. Although 2 cases of
EBVMCU (cases 2 and 5) were included in Ann Arbor stage
IV, each had a favorable clinical outcome.
DISCUSSION
We have shown that the presence of EBVMCU appears to
confer a better prognosis in patients with MTX-LPD. Most
of our patients with positive outcomes had been diagnosed
with EBVMCU. Of the 12 cases of MTX-LPD with muco-
cutaneous ulcer reported in the literature7,10,11,12,13,14,15,16,17
all except 117 were EBV-positive and all 9 cases with
available data showed complete remission without
chemotherapy.
    EBVMCU was first reported to be a favorable prognostic
indicator in a case series of 26 patients (consisting of 19
with Age-LPD and 7 with iatrogenic immunodefici-
ency-associated LPD including 4 with MTX-LPD)7, but the
incidence of EBVMCU in MTX-LPD was not known. Our
study shows that the incidence of EBVMCU in EBV+
MTX-LPD is 42% (5 out of 12), which is higher than that of
EBVMCU in Age-LPD (13%, 16 cases out of 122)18.
    Age-LPD is believed to be a consequence of an under-
lying immunological deficit, or immunosenescence of the T
cell receptor (TCR) repertoire19,20 — a natural degeneration
of the immune system that occurs with aging. Considering
the high average age of our cases, age-related immunosenes-
cence might be partly involved in the development of
MTX-LPD. This may be revealed by decreases in the TCR
repertoire in the future.
    Only a few cases of EBV latency in MTX-LPD have
been reported; those of EBV latency among MTX-LPD,
PT-LPD, and Age-LPD are summarized in Table 421,22,23.
Other case series include 53 cases of LPD in a variety of
autoimmune diseases, including 4 cases of MTX-LPD, in
which all 16 cases of EBV+ LPD were in latency II24. Taken
together, these data suggest that EBV+ MTX-LPD is more
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Table 2. HLA-A, B, and DR alleles of 16 cases of RA with MTX-LPD.
No.             HLA-A                           HLA-B                      HLA-DR
1             11:01/24:02                    35:01/48:01               04:05*/09:01
3             02:01/24:02                    15:11/40:02               09:01/14:02*
4             24:02/26:01                    15:07/40:02                04:03/09:01
5                   24:02                         07:02/52:01               01:01*/15:02
6             02:06/26:01                    15:11/39:01              04:10*/14:06*
7             02:01/26:01                    35:01/55:02               04:05*/04:06
9                   24:02                         07:02/54:01               04:05*/08:02
10                 11:01                         48:01/54:01               04:05*/15:01
11            02:01/02:07                    15:11/46:01                      09:01
12           24:02/26:01                    40:02/52:01               04:05*/09:01
13           02:01/24:02                    40:01/52:01               04:05*/15:02
14           24:02/33:03                    44:03/52:01                08:03/15:02
15                24:02                              52:01                           15:02
18                02:01                         07:02/15:01               01:01*/15:01
19           02:01/02:06                    48:01/54:01               04:05*/04:07
20                24:02                         51:01/59:01              01:01*/04:05*
* Rheumatoid arthritis shared epitope. RA: rheumatoid arthritis;
MTX-LPD: methotrexate-associated lymphoproliferative disorders.
Table 3. Risk allele of RA with MTX-LPD in Japanese population.
                                                                         Total                (+)               (–)             Frequency of Allele        p*                 Pc               OR           95% CI
                                                                    Allele Nos.                                                  in Control Cases                           Value**
HLA-B15:11
  in RA with MTX-LPD, n = 16                       32                   3                29                       0.00961              0.0036           0.061           10.0         3.0–32.8
                                                                                                                                               0.00522              0.0097            0.16            18.5        1.9–183.4
  in RA with MTX-LPD without                       26                   3                23                       0.00961              0.0020           0.032           13.4         4.0–45.0
  EBVMCU, n = 13                                                                                                            0.00522              0.0056           0.090           24.9        2.5–249.5
  in EBV+ RA with MTX-LPD, n = 9              18                   3                15                       0.00961             0.00066         0.0079          18.2         5.3–62.3
                                                                                                                                               0.00522              0.0020           0.024           38.2        3.7–390.0
1 Japanese healthy control. 2 RA control. * 2 × 2 Fisher’s exact study. ** Corrected with Bonferroni’s method. RA: rheumatoid arthritis; MTX-LPD:
methotrexate-associated lymphoproliferative disorders; EBV: Epstein-Barr virus; EBVMCU: EBV-positive mucocutaneous ulcer.
likely to be in latency II, followed by latency III. This obser-
vation also appears to hold true for PT-LPD and Age-LPD.
PT-LPD has been generally categorized as latency III25, but
is often seen to be in latency II. Cases of Age-LPD were also
found to be mainly in latency II. Nonetheless, the latency
classification had no value in predicting the prognosis of
MTX-LPD in our cohort. The utility of EBV latency in
MTX-LPD remains unknown.
    Although the pathogenesis of EBVMCU is unclear,
lymphocytic vasculitis was observed in more than half our
cases of EBVMCU. In EBV-positive LPD, the Mig
monokine, induced by interferon-γ (IFN-γ), and IFN-γ
inducible protein-10 (mainly produced by reactive cells
including endothelial cells) are thought to be powerful insti-
gators of vascular and tissue injuries26. Thus, we hypo-
thesize that tissue necrosis and the impairment of local
blood flow to the area of vascular damage might be pivotal
to the pathogenesis of EBVMCU. Although it is unclear
why patients with MTX-LPD who developed EBVMCU
had a better prognosis, several factors might be responsible.
One possibility is that the mucocutaneous ulcer is so
conspicuous that patients seek medical help more promptly,
when diagnosis is relatively straightforward and the disease
is in an earlier, potentially reversible stage. Thus, the prompt
cessation of MTX may lead to a good outcome.
    Our study is the first, to our knowledge, to have
conducted HLA typing, revealing that HLA-B15:11 could
be a risk allele in EBV+ RA with MTX-LPD. Notably, all 3
HLA-B15:11-positive cases were EBV-positive and 2 were
polymorphic, indicating that this allele may be linked to the
susceptibility to EBV infection and development of LPD. In
our study, HLA-B15:11 had no correlation with
HLA-shared epitopes, RF, or ACPA. To the best of our
knowledge, there have been no reports of any relationship
between this allele and other diseases. The identification of
a genetic risk factor could help to clarify the pathogenesis of
298 The Journal of Rheumatology 2014; 41:2; doi:10.3899/jrheum.130270
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Figure 3. Chemotherapy-free survival. Kaplan-Meier curve shows chemotherapy-free survival within 18
months, comparing patients in the EBV-positive mucocutaneous ulcer (EBVMCU) group with those with
other forms of MTX-LPD. Methotrexate was withdrawn in all cases. *Log-rank test, p < 0.05. MTX-LPD:
methotrexate-associated lymphoproliferative disorders; EBV: Epstein-Barr virus.
Table 4. EBV latency classification among MTX-LPD, PT-LPD, and Age-LPD.
Disease                   Year                  Author                  Cases                    I                      II                    III
PT-LPD                  2003                Birkeland                   16                       1                      8                     7
Age-LPD               2009                   Asano                     26                       0                     19                    7
MTX-LPD             2007                Miyazaki                    3                        0                      1                     2
MTX-LPD             2013         present case series            11                       3                      5                     3
MTX-LPD: methotrexate-associated lymphoproliferative disorders; PT-LPD: posttransplant lymphoprolifer-
ative disorders.
LPD and to achieve safer therapy for patients who might be
at risk of LPD if their RA is treated with MTX. Because this
is a retrospective study, there are some limitations, and a
larger scale prospective trial is needed to clarify the patho-
genesis of this disease.
    We have demonstrated that cases of EBVMCU, a
subgroup of MTX-LPD, were all histologically poly-
morphic and had a more favorable outcome by withdrawing
MTX alone. In addition, we found that the frequency of the
HLA-B15:11 allele was significantly increased in our
cohort, which suggests that it may be a risk factor for EBV+
RA with MTX-LPD.
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